

5 - 6 DEC. 2023

EUROPEAN PARTNERSHIP STAKEHOLDER Forum 2023

BLUE POINT | BRUSSELS

Session A3

Beyond HE funding: Additionality and directionality of European Partnerships

December 5th, 2023, 16.00-17.15 CET

Room Vesalius



Draft Agenda

16:00 Introduction, *Pierre Michel, European Commission*

Directionality and Additionality: Outcomes of the Biennial Monitoring Report

- *Ülle Napa, member of the BMR expert group*

16:15 Additionality/ directionality and national strategies

- *Jakob Just Madsen, MS representative, DK*

16:25 Dimensions of additionality/ directionality in European Partnerships

- *Rainer Sodtke, Biodiversa+*
- *Jesus Contreras, EIT Digital Chief Operations and Financial Officer*

Added value of European Partnership funding compared to other European instruments and national programmes

- *Prof. Klaus Pantel, Director of the Institute of Tumor Biology, University Medical Center Hamburg, Eppendorf, ERC Advanced and PoC Grantee*

17:00 Main conclusions and discussion on future processes and necessities

PARALLEL SESSION A3: BEYOND THE FUNDING: ADDITIONALITY AND DIRECTIONALITY OF EUROPEAN PARTNERSHIPS

ÜLLE NAPA

EXPERT GROUP ON SUPPORT OF THE STRATEGIC COORDINATING PROCESS

ADDITIONALITY AND DIRECTIONALITY IN BMR

The Biennial Monitoring Report (BMR) aims to provide a strong and continuously evolving evidence base to guide the implementation of European Partnerships throughout their life cycles and to inform strategic discussions on Horizon Europe's new policy approach to them.

- 1st BMR was published in 2022
- 2nd BMR will be published in 2024
 - ➡ The preparations and data gathering and analysis is ongoing
 - ➡ The main sources of information for directionality, additionality:
Common indicator Survey and the Country Fiches.

DIRECTIONALITY

The alignment of additional investments and contributions towards common objectives (**directionality**) and the achievement of impacts that cannot be created by other Horizon Europe or national actions alone is the main justification for using a partnership approach (BMR 2022).

Directionality is connected to common indicators:

- Common indicator 3 - Overall (public and private, in-kind and cash) investments mobilised towards EU priorities
- Common indicator 10 - Alignment of national / regional / sectorial policies)

DIFFERENT DIMENSIONS OF DIRECTIONALITY

SOME EXAMPLES FROM COUNTRY FICHES

The MS/AC countries mention the alignment of participation in EU Partnerships with:

- **Smart Specialisation Strategies** (e.g., Greece, Slovenia)
- **National level R&I strategies** (Norway, Estonia, Slovenia etc. EPs have been seen as tools to implement national level priorities, initiatives (Austria)).
- Alignment with the **organisation's priorities**/focus and in addition also **alignment with EU Partnership instruments**. (Belgium example - innovation funding agencies pay attention to topics, but also type of partnerships they participate in.).
- National **supporting measures** for participation in EU Partnerships (sometimes targeted to some specific topics, e.g, example of Croatia)
- Alignment with the most active, competitive or numerous **thematic research groups** (in addition to alignment with national priorities) (Finland, Ireland, Sweden). Sometimes **special activities to support** or promote the areas of strength (e.g, Ireland, Italy, Malta)

DIFFERENT DIMENSIONS OF DIRECTIONALITY

THE COUNTRY FICHES

- Observations from CFs:
 - There could be shift in priorities in FP10 (meaning priorities are quite stable during one funding period)
 - Participation in agenda setting at EU level also important for alignment (mentioned by Italy)
 - Preferred topics for participation – more natural sciences oriented.
 - Centralised vs decentralised R&I system – affects also alignment/funding options – some countries are more flexible than others (Slovenian example)

ADDITIONALITY

An important added value of European Partnerships derives from the **additional** private and/or public R&I investments in EU priorities (additionality) that can be translated into a leverage effect resulting from Union intervention (BMR 2022).

Additionality is connected to common indicator:

- Common indicator 2 - Additional investments triggered by the participation in partnerships, i.e. launch of a complementary national/regional programme to follow-up results or follow-up successful projects or high-quality proposals that were not funded by partnership.

DIFFERENT DIMENSIONS OF ADDITIONALITY

SOME EXAMPLES FROM COUNTRY FICHES

Examples of direct additionality (mobilising funds, creating additional national/transnational level programmes/measures/initiatives/follow-up projects)

- **Follow-up ERA-NET projects/network funding** with national funding (Belgium example IRAsme and CorNet, Croatia has also had similar national level projects).
- Follow-up **cooperation projects between SMEs** (Belgium – it exists, but it is difficult to monitor the projects, as no national funding is involved).
- Austria launched four transformative **national research and innovation missions** that directly correspond to European Partnership and that have the participation to the respective partnerships included in their strategy: Climate Neutral Cities, Clean Energy Transition, Mobility Transition and Circular Economy.
- Developing **research infrastructures** (Spanish example on super computer)

DIFFERENT DIMENSIONS OF ADDITIONALITY

SOME EXAMPLES FROM COUNTRY FICHES

Examples of indirect additionality (creation of central management and monitoring systems of national level co-funding/participating).

- Czech Republic example on **launching a Council for international cooperation in research, development and innovation** – to better manage and participate in EU R&I initiatives. **Programme of Participation** (Estonia).
- Croatian example of **developing the NCP network to support also the participation** in EU partnerships and **supporting the applicants to apply for national and transnational level follow-up programmes.**
- Participation in EU Partnerships creates a **possibility to link sectoral ministries via participation of EU Partnerships more with thematic European R&I** (Czech Republic, Estonia)
- EU Partnerships as **stepping stones towards** Horizon Europe projects (Estonia)



biodiversa+

European Biodiversity Partnership

Biodiversa+ The European biodiversity partnership Additionality and Directionality


Dr. Rainer Sodtke, Biodiversa+ Vice Chair

European Partnership Stakeholder Forum 2023
A3 Beyond HE funding: Additionality and Directionality



What is Biodiversa+?

- The **European biodiversity Partnership** co-funded by the European Commission under Horizon Europe
- **Supporting excellent research on biodiversity with an impact for policy and society**
- Officially launched in Oct. 2021 for a 7 years duration
- Jointly developed by BiodivERsA and the EC (DG R&I and DG Env) – **building on BiodivERsA (2005-2021)**





- **Biodiversa+ members:**

Research actors

- Ministries in charge of research
- Research funding organisations



Policy actors

- Ministries in charge of environment
- Environment protection agencies



Additionality and directionality in Biodiversa+: Financial investments and portfolio of activities



Budget of **>800 Mio € over 7 years**,
combining in-cash and in-kind resources from its Partners
and including **165 Mio €** by the European Commission



Directionality: The Biodiversa+ Strategic Research & Innovation Agenda

Implementation of EU policies:

EU Biodiversity Strategy, EU's global action, EU's commitment to CBD / GBF, IPBES etc.



Common objectives: Flagship programmes

- Multi-annual thematic programmes on **particular issues**
- Aligned with **SRIA** themes
- Encompass a **portfolio of activities**.
- Increased efficiency / impact through cross-linkages

Additionality and directionality: Joint research funding, networking, capacity building

- **Flagship programmes and research calls**

- **2021 Call | Biodiversity protection** ▶ 36 projects >44M€, 38 funding organisations from 28 countries
- **2022 Call | Biodiversity monitoring** ▶ 33 projects recommended for funding for >42.8M€ (**confidential**)
- **2023 Call | Nature-based solutions** ▶ Launched Sept 2023 / decision fall 2024, reserved budget >40M€
- **2024 Call | Societal transformation** ▶ Under development – to be launched in Sept. 2024

- **Networking & clustering events**

- **April 2023, Prague | BiodivProtect Kick-off meeting & clustering workshop**

- **Capacity building activities**

- **Each year | General webinars on our research calls** with ca. 870 participants on average and **targeted webinars** in countries with lower participation/success rate
- **May 2023 | Data management workshop** for the BiodivProtect projects
- Update of the **Guidance document on open science and data management**

Additionality and directionality: Biodiversity monitoring

- **Overall objective:** Towards a transnational network of biodiversity monitoring schemes
- **Good mobilisation** of Biodiversa+ partners & organisations
 - Synergies in **(sub-)national biodiversity monitoring**: interviews, workshops, information meetings
 - Co-design of a **Biodiversity Monitoring Coordination Centre** (with EuropaBON, GBIF, EEA & KCBD)
- **Biodiversity monitoring pilots**
 - Monitoring of **invasive alien species**
 - Monitoring **soil biodiversity** in protected, near-natural forests
 - Comparison of **governance, data interoperability and standards** in biodiversity monitoring
 - *New:* Rocky reef fish monitoring network, Mapping and monitoring of grassland and wetland habitats, **Automated Biodiversity Monitoring Stations**: automated monitoring of birds, bats and nocturnal insects through sound and image recognition
- **Deliverables**
 - Mapping of (sub-)national organisations funding & steering biodiversity monitoring
 - Biodiversity monitoring priorities; data interoperability; use of data in the private sector
 - Strategic biodiversity monitoring report Phase I

Additionality: Private sector and science-policy connection

Nature-based solutions & private sector:

- 2022 | **Strategic Workshop on Nature-based solutions** (*feeding BiodivNBS Call*)
- 2023 | Launch of the **NBS roadmap**



Business & Biodiversity :

- 2023 | **Strategic workshop on Business & Biodiversity**
- Draft **guide on the European R&I landscape business & biodiversity**

Science-policy:

- **Dialogue events** on Transformative Change (*feeding BiodivTransform Call*)
- **Desk studies**
 - Role of biodiversity in NBS (*feeding BiodivNBS Call*)
 - NBS & transformative change (*feeding BiodivTransform Call*)
- **Science-policy forum** on GBF knowledge needs
- **Knowledge hubs**
 - 2023 | Launch of KH on **NBS for adaptation & mitigation of climate change** (BiodivClim)
 - 2023 | Preparation of a KH on **Nature Restoration Law** (with BiodivRestore)
- Collaboration with **BioAgora**



Additionality: Internationalisation of the Partnership

- **Analyses & mapping performed**

- Report on collaboration between scientists of the ERA and other regions
- Mapping of Biodiversa funded projects' outcomes to feed Global policy making


- **Collaboration strategies developed**

- Overarching **Internationalisation Strategy**
- Collaboration with **IPBES** and **MEAs**
- Collaboration with **Research Infrastructures**




- **Relationships with key partners developed or strengthened**

- Strategic discussion with **CBD** & participation in 3 side events at COP15
- 2 dialogue events with **IPBES** & hosting of the knowledge generation TSU
- Global **Research Infrastructures** & Research Funders: 2 strategic workshops (GBIF)
- [May 2023](#) | Joint events with **Belmont Forum** (under BiodivScen)
- **International participation** in (some) Biodiversa+ calls: Brazil, Israel, Ivory Coast, Morocco, South Africa & Taiwan, Tunisia



Additionality: Communication and Outreach

- **Communication framework** developed
 - materials, comms strategy and KPIs, partners' toolkit
- **Biodiversa+ website** developed & launched
- Growth of our **social media following**
- **Animated videos** on Biodiversa projects developed
 - 2 on BiodivScen funded projects on scenarios
 - 1 on BiodivHealth funded projects on coronavirus
- **Press briefings** organized
- **Project & programme database and research infrastructure catalogue**
 - new online user-friendly module
 - Database: estimate growth 50% (ca 15,000 projects)
 - research infrastructure catalogue: estimate growth 50%



	1/10/2021	27/06/2023	Growth
Twitter	3188	5989	87%
LinkedIn	793	3191	302%



Additionality: Building on existing and new initiatives



... and many more!



Impact of additionality and directionality in on national policies

- **Research and innovation**

- Commitments on common flagships / call topics
- Partners' national investments (in-cash / in-kind resources)

- **Biodiversity monitoring**

- Commitment on common goals and priorities (monitoring pilots)
- Alignment / harmonization of monitoring schemes, methods / technologies, databases, standards

- **Environmental policies**

- Input to implementation of CBD (SBSTTA, SBI), GBF (e.g. EBVs, indicators)
- Implementation / refinement of NBSAPs
- Input to IPBES functions / assessments

- **National hubs**

- Set-up of hubs / mirror groups in some partners' countries with several partner organisations

- **Mainstreaming of biodiversity in other sectoral policies / in private sector**

- Nature-based solutions
- Transformation of society and private sector (e.g. agriculture and forestry, (urban) planning, traffic)



biodiversa+
European Biodiversity Partnership

EUROPEAN PARTNERSHIP



Co-funded by
the European Union

Thank you!



www.biodiversa.eu



contact@biodiversa.eu



BiodiversaPlus






EIT DIGITAL


**The Value of an
ecosystem**

Boots on the ground with 23 offices



Unrivalled **partnership**

500+ startups
23 cities
Hub in Silicon Valley



Jumpstarter
Summer Schools
Master School
DeepHack

3500 Talent Pool (Master School Alumni)
Access to Talent Service
60 Universities
350+ Partners

Venture Program
Open Innovation Factory
Growth Services
Access to Finance Program
US Landing Program

EIT Digital is an impact organization

Our ecosystem keeps growing

3,500+ talent pool

1,000+ investors

€160M+ EU funding

60 universities

350+ partners

23 offices

500k MOOC learners

500+ startups

Hub in Silicon Valley

Ecosystem highlights



Meeting with Commissioner Ivanova



EIT Digital and ADRA join forces




Regional Office opening in Cluj-Napoca



Interview with EIC Board President



EIT Digital at Digital SME Alliance Summit



CIEO/CMO on Unstoppable Women list

Innovation highlights



OCTO **WSense** raises €9M Series A




NOV **Rentall** raises €1.25M seed



At WebSummit with EIC/EIF/EIB



Jentis raises €11M Series-A



New equity positions



Cosy Colis partners with UPS

Education highlights



EIT Digital (d)Academy launched




SPECTRO programme kicked-off



Master School Graduation in Madrid



EIT Alumni event at CONNECT23



EIT Digital CEO/CMO at EduTech



Master School Kick-off in Cluj-Napoca



**TARGET
& FOCUS**

Invest for Impact



Deepen and Scale

Delivering Transformation

Harvest for Value



Digital

Accelerate recovery

Include and Succeed

Sustainable growth


- From 25 core partners to 123
- From 5 nodes to 9
- From Labs to Digital
- Setup for Innovation and Education

- 278 partners in 2019
- 2280 students since the 2011
- 15 companies created in 2019
- 69 companies accelerated in 2019

- 350 partners in 2023
- 21 Offices in EU
- 3000 students
- 500 start-ups




Sustainable Knowledge Triangle Integration




Challenges

Innovation as business

Ecosystem as value



- Proactivity
- Multi-Engagement
- Clear ROI



Prof. Dr. med. Klaus Pantel

Direktor, Institut für Tumorbilogie, UKE, University Cancer Center Hamburg (UCCH)

pantel@uke.de

Research Focus:

Basic research: Cancer cell dissemination/metastasis

→ Translational research: „Liquid Biopsy“



My personal EU Funding Journey:

FP6: DISMAL (2005-2009)

ERC Adv Investigator Grants „DISSECT“ & “INJURMET”

ERC PoC Grant „CTCapture“ & CTCapture_2.0“ (2011-2025)

Coordination: IMI „CANCER-ID“ (2015-19), IHI „GUIDE.MRD (2023-28)

Horizon „PANCAID“ (2023-28), TRANSCAN PROLIPSY (2018-2022)




Funded by
the European Union

Thank you !



Biology of Cancer Cell Dissemination/Metastasis




Detection and molecular characterization of disseminating tumor cells

ERC grants & DFG SPP microBONE Consortium

(Hofbauer, Pantel et al, Nat. Rev. Clin. Oncol. 2021; Werner, Heidrich, Pantel, Sem. Cancer Biol. 2022)

Liquid Biopsy: Comprehensive assessment of circulating blood biomarkers




25. APRIL 2019 DIE ZEIT N° 16

ZEIT  HAMBURG

Immobilien
MEISSLER & CO
meissler-co.de

Mai

Mensch des Monats



PANcreatic CAncer Initial Detection via liquid biopsy (PANCAID) EU-Consortium

Universitätsklinikum Hamburg-Eppendorf Hamburg, Germany	Universitätsklinikum Schleswig-Holstein Kiel, Germany
Karolinska Institutet Stockholm, Sweden	Centre Hospitalier Universitaire Montpellier Montpellier, France
Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III Madrid, Spain	Universitätsklinikum Heidelberg Heidelberg, Germany
Medizinische Universität Graz Graz, Austria	Uppsala Universitet Uppsala, Sweden
Umeå Universitet Umeå, Sweden	The Hebrew University of Jerusalem Jerusalem, Israel
Pancreatic Cancer Europe ASBL Brussels, Belgium	Collective Minds Radiology AB Taby, Sweden
concentris research management Fürstenfeldbruck, Germany	Maccabi Sheirutei Briut Foundation Tel Aviv, Israel
	La Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal Madrid, Spain
	The Chancellor Masters and Scholars of The University of Cambridge [UCAM] Cambridge, United Kingdom
	Zava Deutschland GmbH Hamburg, Germany



PARTNERS

Project
duration

5 years

Grant
amount

**9,8 million €
(9,838,840.00 €)**

Partners

**16 partners
+ 1 associated partner from
8 countries**

Project start



1st January 2023

**6 clusters out of 78
applications**

Coordinator: Klaus Pantel, Hamburg; Co-Coordinator: Matthias Löhr, Stockholm

Overview

- Identify biomarker(s) with liquid biopsy to predict and in turn prevent the development of pancreatic cancer
- Test TRL-4 liquid biopsy methods
- Patent and commercialise (ELBS)
- Health economy evaluation
- Reach-out to patient organisations




EU/IMI Project CANCER-ID



Evaluation of technologies for blood-based bio-marker analysis (e.g. CTCs, ctDNA and cfmiRNAs) for tumor liquid biopsy in lung & breast cancer – Companion diagnostics -

- 40 partners from academia and industry
- 5 year project (2015-2019)
- combined budget of 18 Mio €
- ✓ > 50 scientific publications, more added each year



Sustainability after end of project???



ELBS sustains the work of IMI CANCER-ID (2015-2019) - 84 Institutions from Akademia and Industry – (ELBS – “Legacy” (EU/IMI Factsheet 05/2022)

EUROPEAN LIQUID BIOPSY SOCIETY

ACTUAL MEMBERS



ORGANIZATION TEAM



CHAIRMAN | ELBS

Prof. Dr. med. Klaus Pantel

Director of the institute

Center for Experimental Medicine
Institute of Tumor Biology

pantel@uke.de

+49 (0) 40 7410 – 53503



PROJECT MANAGER | ELBS

Dr. Claudia Koch

Center for Experimental Medicine
Institute of Tumor Biology

c.koch@uke.de

+49 (0) 40 7410 – 53503

www.elbs.eu | [LinkedIn](#)

WORKING GROUPS

DISSEMINATION & EDUCATION
MEET 2 TIMES A YEAR

CLINICAL
MEET 2 TIMES A YEAR

TECHNOLOGY
MEET 4 TIMES A YEAR

CTC WORK GROUP
ctDNA WORK GROUP
EV WORK GROUP

REGULATORY
MEET 2 TIMES A YEAR

EL PAIS, November 2023



Consortium – 22 partners

Academic Partners



Patient Partners



Conclusions

- Establishing international networks with top-class partners strengthens UKE/Hamburg/Germany
 - European partnerships strengthen the EU research and innovation landscape (visibility)
 - High international visibility of the coordinator within & beyond Europe (USA, Asia)
 - Synergy effects with corresponding national and European programs
- High translational potential through public-private partnerships (CANCER-ID, ELBS, GUIDE.MRD)
 - Public-private partnership formats (IHI, ELBS) generate great interest in USA (AACR, NCI)

Recommendations for the future:

- Avoid over-regulation: Reduce reporting & control requirements, trust researchers!
- Reduce bureaucratic hurdles: overboarding administrative/regulatory tasks reduce motivation, scientific success and implementation
 - Encourage more public-private partnership programs
 - Strengthen the bridge to other strong research regions (USA, Asia)
 - Strengthen sustainability beyond the funding period (e.g. ELBS)

THANK YOU

#EUPartnership

www.EDITwebsite.eu



© European Union 2023

Unless otherwise noted the reuse of this presentation is authorised under the [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/) license. For any use or reproduction of elements that are not owned by the EU, permission may need to be sought directly from the respective right holders.

Image credits: © ivector #235536634, #249868181, #251163013, #266009682, #273480523, #362422833, #241215668, #244690530, #245719946, #251163053, #252508849, 2020. Source: Stock.Adobe.com. Icons © Flaticon – all rights reserved.